These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1248 related articles for article (PubMed ID: 25867264)
1. IFN-γ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer. Abiko K; Matsumura N; Hamanishi J; Horikawa N; Murakami R; Yamaguchi K; Yoshioka Y; Baba T; Konishi I; Mandai M Br J Cancer; 2015 Apr; 112(9):1501-9. PubMed ID: 25867264 [TBL] [Abstract][Full Text] [Related]
2. Interferon-γ-induced PD-L1 surface expression on human oral squamous carcinoma via PKD2 signal pathway. Chen J; Feng Y; Lu L; Wang H; Dai L; Li Y; Zhang P Immunobiology; 2012 Apr; 217(4):385-93. PubMed ID: 22204817 [TBL] [Abstract][Full Text] [Related]
3. PD-L1 on tumor cells is induced in ascites and promotes peritoneal dissemination of ovarian cancer through CTL dysfunction. Abiko K; Mandai M; Hamanishi J; Yoshioka Y; Matsumura N; Baba T; Yamaguchi K; Murakami R; Yamamoto A; Kharma B; Kosaka K; Konishi I Clin Cancer Res; 2013 Mar; 19(6):1363-74. PubMed ID: 23340297 [TBL] [Abstract][Full Text] [Related]
4. Combined Trabectedin and anti-PD1 antibody produces a synergistic antitumor effect in a murine model of ovarian cancer. Guo Z; Wang H; Meng F; Li J; Zhang S J Transl Med; 2015 Jul; 13():247. PubMed ID: 26219551 [TBL] [Abstract][Full Text] [Related]
5. PD-1 and PD-L1 upregulation promotes CD8(+) T-cell apoptosis and postoperative recurrence in hepatocellular carcinoma patients. Shi F; Shi M; Zeng Z; Qi RZ; Liu ZW; Zhang JY; Yang YP; Tien P; Wang FS Int J Cancer; 2011 Feb; 128(4):887-96. PubMed ID: 20473887 [TBL] [Abstract][Full Text] [Related]
6. Clinical significance of PD-L1-positive cancer-associated fibroblasts in pN0M0 non-small cell lung cancer. Teramoto K; Igarashi T; Kataoka Y; Ishida M; Hanaoka J; Sumimoto H; Daigo Y Lung Cancer; 2019 Nov; 137():56-63. PubMed ID: 31546072 [TBL] [Abstract][Full Text] [Related]
7. Programmed cell death-ligand 1 expression is associated with a favourable immune microenvironment and better overall survival in stage I pulmonary squamous cell carcinoma. Yang CY; Lin MW; Chang YL; Wu CT; Yang PC Eur J Cancer; 2016 Apr; 57():91-103. PubMed ID: 26901614 [TBL] [Abstract][Full Text] [Related]
8. Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma. Freedman RS; Kudelka AP; Kavanagh JJ; Verschraegen C; Edwards CL; Nash M; Levy L; Atkinson EN; Zhang HZ; Melichar B; Patenia R; Templin S; Scott W; Platsoucas CD Clin Cancer Res; 2000 Jun; 6(6):2268-78. PubMed ID: 10873077 [TBL] [Abstract][Full Text] [Related]
9. The IFN-γ/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy. Qian J; Wang C; Wang B; Yang J; Wang Y; Luo F; Xu J; Zhao C; Liu R; Chu Y J Neuroinflammation; 2018 Oct; 15(1):290. PubMed ID: 30333036 [TBL] [Abstract][Full Text] [Related]
10. Chemotherapy Induces Programmed Cell Death-Ligand 1 Overexpression via the Nuclear Factor-κB to Foster an Immunosuppressive Tumor Microenvironment in Ovarian Cancer. Peng J; Hamanishi J; Matsumura N; Abiko K; Murat K; Baba T; Yamaguchi K; Horikawa N; Hosoe Y; Murphy SK; Konishi I; Mandai M Cancer Res; 2015 Dec; 75(23):5034-45. PubMed ID: 26573793 [TBL] [Abstract][Full Text] [Related]
11. Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer. Pan Y; Lu F; Fei Q; Yu X; Xiong P; Yu X; Dang Y; Hou Z; Lin W; Lin X; Zhang Z; Pan M; Huang H J Hematol Oncol; 2019 Nov; 12(1):124. PubMed ID: 31771616 [TBL] [Abstract][Full Text] [Related]
12. Programmed cell death ligand 1 disruption by clustered regularly interspaced short palindromic repeats/Cas9-genome editing promotes antitumor immunity and suppresses ovarian cancer progression. Yahata T; Mizoguchi M; Kimura A; Orimo T; Toujima S; Kuninaka Y; Nosaka M; Ishida Y; Sasaki I; Fukuda-Ohta Y; Hemmi H; Iwahashi N; Noguchi T; Kaisho T; Kondo T; Ino K Cancer Sci; 2019 Apr; 110(4):1279-1292. PubMed ID: 30702189 [TBL] [Abstract][Full Text] [Related]
13. Sensitizing tumors to anti-PD-1 therapy by promoting NK and CD8+ T cells via pharmacological activation of FOXO3. Chung YM; Khan PP; Wang H; Tsai WB; Qiao Y; Yu B; Larrick JW; Hu MC J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34887262 [TBL] [Abstract][Full Text] [Related]
14. Clinicopathological analysis of PD-L1 and PD-L2 expression in pulmonary squamous cell carcinoma: Comparison with tumor-infiltrating T cells and the status of oncogenic drivers. Kim MY; Koh J; Kim S; Go H; Jeon YK; Chung DH Lung Cancer; 2015 Apr; 88(1):24-33. PubMed ID: 25662388 [TBL] [Abstract][Full Text] [Related]
15. Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer. Strickland KC; Howitt BE; Shukla SA; Rodig S; Ritterhouse LL; Liu JF; Garber JE; Chowdhury D; Wu CJ; D'Andrea AD; Matulonis UA; Konstantinopoulos PA Oncotarget; 2016 Mar; 7(12):13587-98. PubMed ID: 26871470 [TBL] [Abstract][Full Text] [Related]
16. Distribution and prognostic relevance of tumor-infiltrating lymphocytes (TILs) and PD-1/PD-L1 immune checkpoints in human brain metastases. Harter PN; Bernatz S; Scholz A; Zeiner PS; Zinke J; Kiyose M; Blasel S; Beschorner R; Senft C; Bender B; Ronellenfitsch MW; Wikman H; Glatzel M; Meinhardt M; Juratli TA; Steinbach JP; Plate KH; Wischhusen J; Weide B; Mittelbronn M Oncotarget; 2015 Dec; 6(38):40836-49. PubMed ID: 26517811 [TBL] [Abstract][Full Text] [Related]
17. Prognostic Implications of Tumor-Infiltrating Lymphocytes in Association With Programmed Death Ligand 1 Expression in Early-Stage Breast Cancer. Park IH; Kong SY; Ro JY; Kwon Y; Kang JH; Mo HJ; Jung SY; Lee S; Lee KS; Kang HS; Lee E; Joo J; Ro J Clin Breast Cancer; 2016 Feb; 16(1):51-8. PubMed ID: 26364145 [TBL] [Abstract][Full Text] [Related]
18. Nafamostat mesilate, a serine protease inhibitor, suppresses interferon-gamma-induced up-regulation of programmed cell death ligand 1 in human cancer cells. Homma S; Hayashi K; Yoshida K; Sagawa Y; Kamata Y; Ito M Int Immunopharmacol; 2018 Jan; 54():39-45. PubMed ID: 29100036 [TBL] [Abstract][Full Text] [Related]
20. Distinct patterns of infiltrating CD8+ T cells in HPV+ and CD68 macrophages in HPV- oropharyngeal squamous cell carcinomas are associated with better clinical outcome but PD-L1 expression is not prognostic. Oguejiofor K; Galletta-Williams H; Dovedi SJ; Roberts DL; Stern PL; West CM Oncotarget; 2017 Feb; 8(9):14416-14427. PubMed ID: 28122336 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]